These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26841882)

  • 21. "Stay away from them until you're old enough to make a decision": tobacco company testimony about youth smoking initiation.
    Wakefield M; McLeod K; Perry CL
    Tob Control; 2006 Dec; 15 Suppl 4(Suppl 4):iv44-53. PubMed ID: 17130624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Scottish court dismisses a historic smoker's suit.
    Friedman L; Daynard R
    Tob Control; 2007 Oct; 16(5):e4. PubMed ID: 17897973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tobacco industry strategies for influencing European Community tobacco advertising legislation.
    Neuman M; Bitton A; Glantz S
    Lancet; 2002 Apr; 359(9314):1323-30. PubMed ID: 11965294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attempts to undermine tobacco control: tobacco industry "youth smoking prevention" programs to undermine meaningful tobacco control in Latin America.
    Sebrié EM; Glantz SA
    Am J Public Health; 2007 Aug; 97(8):1357-67. PubMed ID: 17600260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The 'common knowledge' of Quebecers: quantifying the evidence of historians testifying for defendant tobacco companies.
    Callard C
    Tob Control; 2016 Sep; 25(5):492-7. PubMed ID: 26614760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Shared vision, shared vulnerability: A content analysis of corporate social responsibility information on tobacco industry websites.
    McDaniel PA; Cadman B; Malone RE
    Prev Med; 2016 Aug; 89():337-344. PubMed ID: 27261411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of strategic funding by the tobacco industry of medical expert witnesses appearing for the defence in the Aho Finnish product liability case.
    Hiilamo HT
    Addiction; 2007 Jun; 102(6):979-88. PubMed ID: 17523993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tobacco control implications of the first European product liability suit.
    Hiilamo HT
    Tob Control; 2005 Feb; 14(1):22-30. PubMed ID: 15735296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ARTIST (Asian regional tobacco industry scientist team): Philip Morris' attempt to exert a scientific and regulatory agenda on Asia.
    Tong EK; Glantz SA
    Tob Control; 2004 Dec; 13 Suppl 2(Suppl 2):ii118-24. PubMed ID: 15564214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tobacco industry attempts to influence and use the German government to undermine the WHO Framework Convention on Tobacco Control.
    Grüning T; Weishaar H; Collin J; Gilmore AB
    Tob Control; 2012 Jan; 21(1):30-8. PubMed ID: 21659448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "A good personal scientific relationship": Philip Morris scientists and the Chulabhorn Research Institute, Bangkok.
    Mackenzie R; Collin J
    PLoS Med; 2008 Dec; 5(12):1737-48. PubMed ID: 19108600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Systematic Review of Tobacco Industry Tactics in Southeast Asia: Lessons for Other Low- And MiddleIncome Regions.
    Amul GGH; Tan GPP; van der Eijk Y
    Int J Health Policy Manag; 2021 Jun; 10(6):324-337. PubMed ID: 32610812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology of the third wave of tobacco litigation in the United States, 1994-2005.
    Douglas CE; Davis RM; Beasley JK
    Tob Control; 2006 Dec; 15 Suppl 4(Suppl 4):iv9-16. PubMed ID: 17130629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tobacco industry's 'behind the scenes' tactics in Singapore.
    van der Eijk Y; Tan GPP
    Tob Control; 2023 May; 32(3):280-286. PubMed ID: 34452987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Seeking out 'easy targets'? Tobacco companies, health inequalities and public policy.
    Clifford D; Hill S; Collin J
    Tob Control; 2014 Nov; 23(6):479-83. PubMed ID: 23832052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Creating demand for foreign brands in a 'home run' market: tobacco company tactics in South Korea following market liberalisation.
    Lee S; Lee K; Holden C
    Tob Control; 2014 May; 23(3):e8. PubMed ID: 23152099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tracking the relevance of the WHO Framework Convention on Tobacco Control in legislation and litigation through the online resource, Tobacco Control Laws.
    Muggli ME; Zheng A; Liberman J; Coxon N; Candler L; Donley K; Lambert P
    Tob Control; 2014 Sep; 23(5):457-60. PubMed ID: 23644394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. "Accommodating" smoke-free policies: tobacco industry's Courtesy of Choice programme in Latin America.
    Sebrié EM; Glantz SA
    Tob Control; 2007 Oct; 16(5):e6. PubMed ID: 17897975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Smokeless tobacco control: Litigation & judicial measures from Southeast Asia.
    Yadav A; Singh A; Khadka BB; Amarasinghe H; Yadav N; Singh R
    Indian J Med Res; 2018 Jul; 148(1):25-34. PubMed ID: 30264751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The p53 tumour suppressor gene and the tobacco industry: research, debate, and conflict of interest.
    Bitton A; Neuman MD; Barnoya J; Glantz SA
    Lancet; 2005 Feb 5-11; 365(9458):531-40. PubMed ID: 15705463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.